Emerging Anemia Treatments for Dialysis Patients: A Closer Look at HIF-PHIs

March 26, 2025

For over 500,000 Americans on dialysis because of chronic kidney disease (CKD), anemia remains a significant challenge. While the traditional treatment with erythropoietin-stimulating agents (ESAs) has been the standard, recent advancements have introduced a new class of drugs known as Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHIs). These drugs represent a potential shift in managing anemia, though healthcare providers are encouraged to proceed with caution.

Understanding Anemia in Dialysis Patients

Anemia, characterized by a lack of sufficient healthy red blood cells, leads to symptoms like fatigue and weakness, dramatically affecting the quality of life for dialysis patients. ESAs have been used to address this issue by stimulating red blood cell production. However, ESAs can have side effects, especially in elderly patients, including hyporesponsiveness and increased risks of myocardial infarction, heart failure, and strokes. Consequently, researchers have been exploring new treatment avenues, leading to the development of HIF-PHIs.

The Innovative Approach of HIF-PHIs

HIF-PHIs offer a novel mechanism to manage anemia by stabilizing hypoxia-inducible factors (HIFs), which trigger the natural processes of erythropoietin production and iron metabolism. This approach seeks to replicate the body’s response to low oxygen levels, thereby enhancing red blood cell production naturally. A recent meta-analysis published in the Indian Journal of Nephrology in 2025 provides evidence supporting HIF-PHIs as a "feasible alternative" to ESAs for anemia in dialysis-dependent CKD patients. The study, involving 20 randomized controlled trials and nearly 15,000 participants, paints a nuanced picture of the varying efficacy and safety profiles of HIF-PHIs.

Daprodustat: A Promising Alternative

The meta-analysis highlights daprodustat as a particularly promising candidate. This drug has been shown to reduce the necessity for intravenous iron supplementation—a significant inconvenience for dialysis patients. While more research is needed to confirm its long-term safety, current data suggest daprodustat could offer substantial benefits over ESAs, particularly in minimizing the need for additional treatments.

Roxadustat: A Case for Caution

On the other hand, roxadustat presents a more complicated case. Linked to increased treatment-emergent adverse events, its safety profile has raised concerns. This was underscored by the FDA’s initial rejection of the drug in 2021, reflecting ongoing safety considerations. As of March 2025, its approval status in the U.S. remains unchanged, and physicians are advised to carefully evaluate risks versus benefits.

Mixed Results with Other HIF-PHIs

Other drugs in the HIF-PHI class, such as vadadustat, molidustat, enarodustat, and desidustat, showed little distinction from ESAs in effectiveness, necessitating further research to clarify their roles in anemia management.

Implications for U.S. Healthcare Providers

This meta-analysis offers critical insights into the potential for HIF-PHIs in the U.S. healthcare landscape. It underscores the importance of individualized treatment, as not all HIF-PHIs are created equal. Daprodustat appears beneficial in reducing the need for intravenous iron, while more investigation is essential for other agents. Roxadustat’s safety concerns highlight the importance of rigorous evaluation for any new treatment.

U.S. healthcare providers must continue to base decisions on solid evidence, awaiting more comprehensive clinical trials to cement the place of HIF-PHIs in anemia treatment for dialysis patients.

Looking to the Future

The advent of HIF-PHIs marks a significant development in anemia management, holding the promise of improved patient outcomes and a reduced reliance on invasive treatments. However, the path forward requires meticulous research, extensive clinical trials, and vigilant post-market surveillance to ensure these drugs meet the high standards of safety and efficacy expected in the U.S. healthcare system.

In conversations with experts like Dr. Sharma, it emerges that patient-centric approaches and open dialogue between healthcare providers and patients are vital. As the use of HIF-PHIs evolves, these discussions will be crucial in navigating the complexities of anemia management for dialysis patients.

Archyde.com is committed to delivering accurate and up-to-date information on medical advancements. For personalized medical advice, please consult with a qualified healthcare professional.